The role of vitamin D in cancer prevention and treatment.

[1]  C. Davis,et al.  Vitamin D and colon cancer , 2011, Expert review of gastroenterology & hepatology.

[2]  Wei-dong Yu,et al.  CYP24A1 inhibition enhances the antitumor activity of calcitriol. , 2010, Endocrinology.

[3]  Wei-dong Yu,et al.  1,25D3 Enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models , 2010, Cancer.

[4]  E. Petricoin,et al.  Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. , 2009, The Journal of urology.

[5]  S. Srinivas,et al.  A phase II trial of calcitriol and naproxen in recurrent prostate cancer. , 2009, Anticancer research.

[6]  D. Feldman,et al.  Unraveling insulin-like growth factor binding protein-3 actions in human disease. , 2009, Endocrine reviews.

[7]  G. P. Studzinski,et al.  Vitamin D and differentiation in cancer , 2009, Critical reviews in clinical laboratory sciences.

[8]  Tai C. Chen,et al.  Vitamin D for the prevention and treatment of pancreatic cancer. , 2009, World journal of gastroenterology.

[9]  V. Arndt,et al.  Meta‐analysis: longitudinal studies of serum vitamin D and colorectal cancer risk , 2009, Alimentary pharmacology & therapeutics.

[10]  E. Raymond,et al.  Dose finding and safety analysis of inecalcitol in combination with a docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Fakih,et al.  A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors , 2009, Cancer Chemotherapy and Pharmacology.

[12]  Bryan M. Gillard,et al.  Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. , 2009, Cancer research.

[13]  E. Giovannucci,et al.  Vitamin D and Prevention of Colorectal Adenoma: A Meta-analysis , 2008, Cancer Epidemiology Biomarkers & Prevention.

[14]  P. Hershberger,et al.  1α,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model , 2008, Molecular Cancer Therapeutics.

[15]  A. Mantovani,et al.  Cancer and inflammation: a complex relationship. , 2008, Cancer letters.

[16]  J. K. Kundu,et al.  Inflammation: gearing the journey to cancer. , 2008, Mutation research.

[17]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[18]  J. Meyerhardt,et al.  Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Nilanjan Chatterjee,et al.  Serum vitamin D concentration and prostate cancer risk: a nested case-control study. , 2008, Journal of the National Cancer Institute.

[20]  Masao Omata,et al.  Inflammation and cancer: Role of nuclear factor‐kappaB activation , 2008, Cancer science.

[21]  D. McNeel,et al.  Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer , 2008, Clinical Cancer Research.

[22]  E. Rankin,et al.  The role of hypoxia-inducible factors in tumorigenesis , 2008, Cell Death and Differentiation.

[23]  N. Kyprianou,et al.  Targeting vasculature in urologic tumors: Mechanistic and therapeutic significance , 2008, Journal of cellular biochemistry.

[24]  P. Allavena,et al.  Pathways connecting inflammation and cancer. , 2008, Current opinion in genetics & development.

[25]  W. Fawzi,et al.  Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: Reanalysis of Women's Health Initiative randomized trial , 2007, International journal of cancer.

[26]  J. Welsh.  Targets of Vitamin D Receptor Signaling in the Mammary Gland , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  D. Peehl,et al.  Vitamin D and prostate cancer. , 1995, Advances in experimental medicine and biology.

[28]  Z. Tulassay,et al.  Carcinogenesis in Inflammatory Bowel Disease , 2007, Digestive Diseases.

[29]  D. Trump,et al.  Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.

[30]  D. S. St. Clair,et al.  Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1α,25-dihydroxyvitamin D3 in prostate cancer cells , 2007, Molecular Cancer Therapeutics.

[31]  M. Schwab,et al.  Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signalling. , 2007, Molecular immunology.

[32]  R. Kurzrock,et al.  Vascular Endothelial Growth Factor and Its Relationship to Inflammatory Mediators , 2007, Clinical Cancer Research.

[33]  L. Mosekilde,et al.  [Vitamin D and breast cancer]. , 2007, Ugeskrift for laeger.

[34]  D. Dang,et al.  1α,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells , 2007, Molecular Cancer Therapeutics.

[35]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[36]  C. Ryan,et al.  Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer , 2007, Cancer Chemotherapy and Pharmacology.

[37]  N. Nowak,et al.  Epigenetic Silencing of CYP24 in Tumor-derived Endothelial Cells Contributes to Selective Growth Inhibition by Calcitriol* , 2007, Journal of Biological Chemistry.

[38]  E. Giovannucci,et al.  Vitamin D and prevention of breast cancer: Pooled analysis , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[39]  E. Bajna,et al.  A 24-Phenylsulfone Analog of Vitamin D Inhibits 1α,25-Dihydroxyvitamin D3 Degradation in Vitamin D Metabolism-Competent Cells , 2007, Journal of Pharmacology and Experimental Therapeutics.

[40]  A. Hutson,et al.  A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.

[41]  C. Redfern,et al.  Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Bonanomi,et al.  The Vitamin D analogue TX 527 blocks NF-κB activation in peripheral blood mononuclear cells of patients with Crohn's disease , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[43]  G. Schwartz,et al.  Vitamin D status and cancer: new insights , 2007, Current opinion in clinical nutrition and metabolic care.

[44]  R. DiPaola,et al.  Vitamin D Inhibits the Formation of Prostatic Intraepithelial Neoplasia in Nkx3.1; Pten Mutant Mice , 2006, Clinical Cancer Research.

[45]  Wei-dong Yu,et al.  Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. , 2006, Cancer research.

[46]  W. Willett,et al.  Vitamin D Intake and the Risk for Pancreatic Cancer in Two Cohort Studies , 2006, Cancer Epidemiology Biomarkers & Prevention.

[47]  Jorge Yao,et al.  1 a , 25-dihydroxyvitamin D 3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis , 2006 .

[48]  Jun Sun,et al.  Increased NF-κB activity in fibroblasts lacking the vitamin D receptor , 2006 .

[49]  E. Crawford,et al.  A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone‐refractory prostate cancer , 2006, Cancer.

[50]  A. Muñoz,et al.  Effects of 1α,25-Dihydroxyvitamin D3 in Human Colon Cancer Cells , 2006 .

[51]  H. Koeffler,et al.  Vitamin D compounds: activity against microbes and cancer. , 2006, Anticancer research.

[52]  D. Peehl,et al.  Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. , 2006, Cancer research.

[53]  J. Lovato,et al.  Phase I/II Study of 19-nor-1α-25-Dihydroxyvitamin D2 (Paricalcitol) in Advanced, Androgen-Insensitive Prostate Cancer , 2005, Clinical Cancer Research.

[54]  D. Trump,et al.  Pharmacokinetics and Tolerability of a Single Dose of DN-101, a New Formulation of Calcitriol, in Patients with Cancer , 2005, Clinical Cancer Research.

[55]  H. Koeffler,et al.  Vitamin D compounds in leukemia , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[56]  David Feldman,et al.  Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. , 2005, Cancer research.

[57]  A. Whittemore,et al.  Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. , 2005, The Journal of urology.

[58]  Georg Bartsch,et al.  Interleukin‐6 regulation of prostate cancer cell growth , 2005, Journal of cellular biochemistry.

[59]  D. Trump,et al.  Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation , 2005, Cancer Chemotherapy and Pharmacology.

[60]  M. Gross.  Vitamin D and calcium in the prevention of prostate and colon cancer: new approaches for the identification of needs. , 2005, The Journal of nutrition.

[61]  S. Nicosia,et al.  Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  Mark F McCarty,et al.  Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy , 2004, Integrative cancer therapies.

[63]  T. Kensler,et al.  Potent, Selective and Low-Calcemic Inhibitors of CYP24 Hydroxylase: 24-Sulfoximine Analogues of the Hormone 1α,25-Dihydroxyvitamin D3 , 2004 .

[64]  J. Brooks,et al.  Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[65]  M. Garzotto,et al.  High-Dose Calcitriol and Carboplatin in Metastatic Androgen-Independent Prostate Cancer , 2004, American journal of clinical oncology.

[66]  S. Kato,et al.  1α, 25-Dihydroxyvitamin D3 is a preventive factor in the metastasis of lung cancer , 2004 .

[67]  S. Itzkowitz,et al.  Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[68]  J. Brooks,et al.  Analysis of vitamin D‐regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays , 2004, The Prostate.

[69]  P. Malloy,et al.  Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. , 2004, Molecular endocrinology.

[70]  P. Hershberger,et al.  Anti-tumor activity of calcitriol: pre-clinical and clinical studies , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[71]  J. Lewin,et al.  Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. , 2004, Cancer research.

[72]  E. Giovannucci,et al.  Plasma 1,25-Dihydroxy- and 25-Hydroxyvitamin D and Subsequent Risk of Prostate Cancer , 2004, Cancer Causes & Control.

[73]  D. Trump,et al.  Pharmacokinetics of 1α,25-Dihydroxyvitamin D3 in Normal Mice after Systemic Exposure to Effective and Safe Antitumor Doses , 2004, Oncology.

[74]  Theodore L DeWeese,et al.  Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment , 2004, Journal of cellular biochemistry.

[75]  M. Lucia,et al.  Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. , 2004, The Journal of urology.

[76]  E. Yang,et al.  Vitamin D Inhibits G1 to S Progression in LNCaP Prostate Cancer Cells through p27Kip1 Stabilization and Cdk2 Mislocalization to the Cytoplasm* , 2003, Journal of Biological Chemistry.

[77]  A. Giaccia,et al.  HIF-1 as a target for drug development , 2003, Nature Reviews Drug Discovery.

[78]  G. Wilding,et al.  Phase II Study of 1α-Hydroxyvitamin D2 in the Treatment of Advanced Androgen-independent Prostate Cancer , 2003 .

[79]  G. Luo,et al.  Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation , 2003, Oncogene.

[80]  J. Dancey,et al.  A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma , 2003, British Journal of Cancer.

[81]  Kelly Smith,et al.  Vitamin D-3 receptor as a target for breast cancer prevention. , 2003, The Journal of nutrition.

[82]  M. Egorin,et al.  Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  P Jack Hoopes,et al.  The combination of a potent vitamin D3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[84]  G. Semenza,et al.  Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. , 2003, Cancer research.

[85]  Jie Liao,et al.  Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. , 2003, Carcinogenesis.

[86]  D. Peehl,et al.  Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression , 2003, Journal of cellular biochemistry.

[87]  P. Hershberger,et al.  Pharmacokinetics of high‐dose oral calcitriol: Results from a phase 1 trial of calcitriol and paclitaxel , 2002, Clinical pharmacology and therapeutics.

[88]  D. Peehl,et al.  Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. , 2002, The Journal of urology.

[89]  R. Mazess,et al.  Phase I trial of 1α-hydroxyvitamin D2 in patients with hormone refractory prostate cancer , 2002 .

[90]  J. Schellens,et al.  Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. , 2002, Molecular cancer therapeutics.

[91]  D. Trump,et al.  Antiproliferative Effects of 1α,25-Dihydroxyvitamin D3 and Vitamin D Analogs on Tumor-Derived Endothelial Cells. , 2002, Endocrinology.

[92]  M. Karin,et al.  Missing Pieces in the NF-κB Puzzle , 2002, Cell.

[93]  H. Gogas,et al.  A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer , 2002, British Journal of Cancer.

[94]  Michael Karin,et al.  NF-κB at the crossroads of life and death , 2002, Nature Immunology.

[95]  Michael J Thun,et al.  Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.

[96]  W. Isaacs,et al.  Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. , 2001, Cancer Research.

[97]  J. Welsh,et al.  A non-calcemic sulfone version of the vitamin D(3) analogue seocalcitol (EB 1089): chemical synthesis, biological evaluation and potency enhancement of the anticancer drug adriamycin. , 2001, Bioorganic & medicinal chemistry.

[98]  J. Bartek,et al.  Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. , 2001, Molecular endocrinology.

[99]  T. Beer,et al.  A Phase I trial of pulse calcitriol in patients with refractory malignancies , 2001, Cancer.

[100]  P. Hershberger,et al.  Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[101]  P. Cohen,et al.  Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. , 2001, The Journal of urology.

[102]  J. Welsh,et al.  Role of Mitochondria and Caspases in Vitamin D-mediated Apoptosis of MCF-7 Breast Cancer Cells* , 2001, The Journal of Biological Chemistry.

[103]  M. Hakama,et al.  Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland) , 2000, Cancer Causes & Control.

[104]  N. Bundred,et al.  1α,25-Dihydroxyvitamin D3 Inhibits Angiogenesis In Vitro and In Vivo , 2000 .

[105]  D. Feldman,et al.  1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration , 2000, Molecular and Cellular Endocrinology.

[106]  H. Koeffler,et al.  Induction of apoptosis by vitamin D3 analogue EB1089 in NCI‐H929 myeloma cells via activation of caspase 3 and p38 MAP kinase , 2000, British journal of haematology.

[107]  J. Keski‐Oja,et al.  1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[108]  C. N. Coleman,et al.  Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen , 1999, Oncogene.

[109]  J. Epstein,et al.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. , 1999, The American journal of pathology.

[110]  N. Weigel,et al.  Vitamin D and Prostate Cancer , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[111]  D. Feldman,et al.  Liarozole Acts Synergistically with 1α,25-Dihydroxyvitamin D3 to Inhibit Growth of DU 145 Human Prostate Cancer Cells by Blocking 24-Hydroxylase Activity. , 1999, Endocrinology.

[112]  E. Gelmann,et al.  Tumor necrosis factor-alpha sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis. , 1999, Cancer research.

[113]  G. Miller,et al.  1α,25-Dihydroxyvitamin D3 and Platinum Drugs Act Synergistically to Inhibit the Growth of Prostate Cancer Cell Lines , 1999 .

[114]  B. Wolff,et al.  1α,25‐Dihydroxyvitamin D3 decreases DNA binding of nuclear factor‐κB in human fibroblasts , 1998 .

[115]  R. Coombes,et al.  A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. , 1998, British Journal of Cancer.

[116]  T. Stamey,et al.  Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) , 1998, The Journal of urology.

[117]  M. Álvarez-Dolado,et al.  1,25‐Dihydroxyvitamin D3 inhibits tenascin‐C expression in mammary epithelial cells , 1998, FEBS letters.

[118]  A. E. Rogers,et al.  Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. , 1997, The Journal of clinical investigation.

[119]  R. Day,et al.  Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. , 1997, Urology.

[120]  M. Campbell,et al.  Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. , 1997, Journal of molecular endocrinology.

[121]  N. Weigel,et al.  1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. , 1997, Endocrinology.

[122]  H. Koeffler,et al.  Vitamin D3 analogs inhibit growth and induce differentiation in LA-N-5 human neuroblastoma cells , 1996, Clinical & Experimental Metastasis.

[123]  S Majewski,et al.  Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. , 1996, The journal of investigative dermatology. Symposium proceedings.

[124]  S. Manolagas,et al.  Down-regulation of NF-kappa B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[125]  G. Miller,et al.  Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[126]  E. Corder,et al.  Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[127]  R. Day,et al.  Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. , 1995, Urologic oncology.

[128]  E. Corder,et al.  Vitamin D and prostate cancer: a prediagnostic study with stored sera. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[129]  G. Schwartz,et al.  Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation , 1992, Cancer.

[130]  R. Coombes,et al.  Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. , 1992, Biochemical pharmacology.

[131]  J. Gallagher,et al.  Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. , 1990, Annals of internal medicine.

[132]  Schwartz Gg,et al.  Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). , 1990 .

[133]  J. Gallagher.  Metabolic effects of synthetic calcitriol (Rocaltrol) in the treatment of postmenopausal osteoporosis. , 1990, Metabolism: clinical and experimental.

[134]  C. Garland,et al.  SERUM 25-HYDROXYVITAMIN D AND COLON CANCER: EIGHT-YEAR PROSPECTIVE STUDY , 1989, The Lancet.

[135]  R. Coombes,et al.  VITAMIN D AND BREAST CANCER , 1989, The Lancet.

[136]  E. Giovannucci.  Vitamin D status and cancer incidence and mortality. , 2008, Advances in experimental medicine and biology.

[137]  D. Dang,et al.  1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. , 2007, Molecular cancer therapeutics.

[138]  S. Yeh,et al.  1α,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases , 2005 .

[139]  Jun Sun,et al.  Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. , 2006, American journal of physiology. Endocrinology and metabolism.

[140]  A. Muñoz,et al.  Effects of 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. , 2006, Anticancer research.

[141]  S. Kato,et al.  1 alpha,25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. , 2005, Carcinogenesis.

[142]  C. Rochlitz,et al.  Cytotoxicity of ketoconazole in malignant cell lines , 2004, Cancer Chemotherapy and Pharmacology.

[143]  T. Kensler,et al.  Potent, selective and low-calcemic inhibitors of CYP24 hydroxylase: 24-sulfoximine analogues of the hormone 1alpha,25-dihydroxyvitamin D(3). , 2004, Journal of medicinal chemistry.

[144]  Edgar M Moran,et al.  Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. , 2002, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[145]  S. Miettinen,et al.  Antiproliferative action of vitamin D. , 2002, Vitamins and hormones.

[146]  D. Trump,et al.  Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. , 2002, Endocrinology.

[147]  Michael Karin,et al.  NF-kappaB at the crossroads of life and death. , 2002, Nature immunology.

[148]  D. Feldman,et al.  Vitamin D: Biology, Actions, and Clinical Implications , 2001 .

[149]  N. Bundred,et al.  1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. , 2000, Circulation research.

[150]  T. McDonnell,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society Calcitriol-Induced Apoptosis in LNCaP Cells Is Blocked By Overexpression of Bcl-2* , 1999 .

[151]  D. Feldman,et al.  Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. , 1999, Endocrinology.

[152]  C. N. Coleman,et al.  Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. , 1999, Oncogene.

[153]  B. Wolff,et al.  1Alpha,25-dihydroxyvitamin D3 decreases DNA binding of nuclear factor-kappaB in human fibroblasts. , 1998, FEBS letters.

[154]  L. Binderup,et al.  Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. , 1997, British Journal of Cancer.

[155]  David C. Smith,et al.  Antiproliferative effects in vitro and in vivo of 1,25-dihydroxyvitamin D3 and a vitamin D3 analog in a squamous cell carcinoma model system , 1995 .

[156]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[157]  B. Hulka,et al.  Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). , 1990, Anticancer research.

[158]  C. Garland,et al.  Do sunlight and vitamin D reduce the likelihood of colon cancer? , 1980, International journal of epidemiology.